DOCSLIB.ORG

United States Patent (19) 11 4,346,246 Terrell Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 4,346,246 Terrell Et Al United States Patent (19) 11 4,346,246 Terrell et al. 45) Aug. 24, 1982 54 PROCESS FOR ADJUSTING THE HALOGEN 58 Field of Search ................................ 568/683, 684 CONTENT OF HALOGENATED ALIPHATIC (56) References Cited ETHERS U.S. PATENT DOCUMENTS (75) Inventors: Ross C. Terrell, Clark; Kirsten Hansen, Berkeley Heights, both of 4,149,018 6/1979 Bell et al. ............................ 568/684 N.J. Primary Examiner-Howard T. Mars Assignee: Airco, Inc., Montvale, N.J. Attorney, Agent, or Firm-Roger M. Rathbun; Larry R. (73) Cassett 21 Appl. No.: 149,360 (57) ABSTRACT 22 Filed: May 13, 1980 Process for adjusting the halogen content of haloge nated aliphatic ethers, by selective replacement of a Related U.S. Application Data halide substituent on the ether with a hydrogen. The (63) Continuation of Ser. No. 19,953, Mar. 12, 1979, aban process is particularly useful for the production of cer doned. tain inhalant anesthetics. (51) Int. Cl. ....................... C07C 41/01; CO7C 41/24 52) U.S. C. ..................................... 568/684; 568/683 9 Claims, No Drawings 4,346,246 1 2 PROCESS FOR ADJUSTING THE HALOGEN where B is OH or OR. CONTENT OF HALOGENATED ALPHATIC Second, dehydrohalogenation may occur. In this ETHERS * , reaction, hydrogen and halogen are removed from adja This is a continuation of application Ser. No. 19,953, cent carbon atoms to form a double bond: filed Mar. 12, 1979, now abandoned. INTRODUCTION This invention relates to processes for adjusting the 10 Ro---R - B se ro---R halogen content of halogenated aliphatic ethers, by R. R. R. R. selective reduction, i.e., replacement of a halide substit uent on the ether with a hydrogen. More specifically, This type of reaction is described in U.S. Pat. No. the invention is concerned with new processes, and 2,803,666, where this reaction occurs: with improvements in existing processes, for the pro 15 duction of certain halogenated aliphatic ethers that are useful as inhalant-anesthetics. (CCl3CHC),O + C2H5OH + KOH Ce BACKGROUND CCl2FCCIOCCl=CCl2. The halogenated ether, 1,2-trifluoro-2-chloroethyl 20 It is also described by Corley et al. in 78 JACS 3489 at difluoromethyl ether, CHF2OCF2CHFC, is a valuable 3491 and 3492, as for example in this preparation: inhalantanesthetic, enflurane, made and sold under the trademark ETHRANE by Airco, Inc., Montvale, N.J. 07645. It is referred to hereafter as enflurane. The presently-employed process for manufacturing 25 this anesthetic material generates a number of by-pro duct streams, each characterized by having more chlo Third, selective reduction may take place, in accor rine in the molecule than does the desired anesthetic dance with the present invention. In this reaction the product. One such by-product stream contains the con halogen is replaced by hydrogen, as in the examples of pound of CF2HOCF2CFCI2, which is very difficult to 30 this application. remove from the desired product by distillation or other In order for the reduction reaction to work, the ether separating technique, and of course it represents a yield must not undergo a hydrolysis or nucleophilic displace loss for the presently-employed process. ment reaction or dehydrohalogenation reaction, which Other by-product streams are produced in the pre is faster than the reduction. In addition, any ether sently-employed process as "bottoms” from the vacuum 35 formed by the reduction reaction must not undergo stills. These bottoms contain the following components further reactions, especially dehydrohalogenation. in varying proportions: . .'', . In order for selective reduction to take place, rather CHCIOCF2CHFC than hydrolysis or nucleophilic displacement or dehy CCl3OCF2CHFC drohalogenation, certain conditions must be met. The CCHOCF2CHFC1 reactions of the halogenated ethers have been little ... CC12HOCF2CFC2 explored and have been considered highly unpredict CCIH2OCF2CFCl2 able. The present invention is remarkable in that only AtCCl3OCF2CFCI2 the present time, these materials... - are useless by-pro certain halogenated ethers can be selectively reduced, ducts that reduce the efficiency of the currently 45 and in that the reduction is selective. employed process. SUMMARY OF THE INVENTION Another important halogenated etheranesthetic is It has now been discovered that selective replace 1-chloro-2-trifluoro difluoromethyl ether, ment of a chlorine or bromine substituent on certain CF3CHCIOCHF2, isoflurane, made and sold under the 50 halogenated aliphatic ethers, with hydrogen, can be trademark FORANE by Airco, Inc. It is referred to accomplished by reacting one of the certain substituted hereafter as isoflurane. In the process for manufacturing ethers with an alkanol and a base, preferably but not this anesthetic, care must be exercised to avoid by-pro necessarily in the presence of a catalyst. The halogen duct formation, and the process now in use achieves replaced may be bonded to a terminal carbon or to an low conversions to the desired product. Representative 55 inner carbon. by-products produced include CF3CCl2OCHF2, which The process of the invention can be concisely de has been considered to be useless in the past. scribed as a process for replacing a halogen substituent The selective reduction of halogenated aliphatic with hydrogen in a halogenated aliphatic ether of the ethers is extremely difficult to accomplish because of methyl-ethyl or ethyl-ethyl type, comprising reacting the different responses exhibited by ethers of this kind 60 with a primary or secondary alkanol and an inorganic to a given reactant or to given reactants. Thus, there are base a halogenated aliphatic ether of the formula: three important reactions that halogenated aliphatic (a) CX3OCY2CZ3 ethers may undergo in the presence of a base. where - First, a hydrolysis or nucleophilic displacement reac tion may occur. This is a reaction in which the halogen 65, andCX3 is CF3, CH3, CH2F, CF2CL, CF2Br, or CHF2; atom is replaced by OH, OR, or other nucleophilic CZ3CY2 is CF3CCL2, CF3CCIBr, CF3CBr2, group, as represented by the equation: ". CFCl2CF2, CFCl2CFCl, CFCl2CFBr, CFBrC1CF, CFCIBrCFC), CFBrCICFBr, 4,346,246 3 4. CCl3CF2, CFBr2CF2, CFBr2CFC1, CFBr2CFBr, chlorine or one bromine is selectively replaced with CCl2BrCF2, CCIBr2CF2 or CBr3CF2 hydrogen. This is a rather remarkable reaction because O it occurs despite the presence on the same molecule of (b) CX3CY2OCY2CX3 -CF3 or where at least one of the CX3CY2 groups is selected from the following: F F --C- or F-C- X X 10 groups, where X is chlorine or bromine. It is also a very valuable reaction because it is specific and permits the and the other CX3CY2 group may be the same or may conversion of previously useless by-products to valu be selected from the following: able products, and also offers a new tool for synthesis. The two primary areas of immediate commercial CF3CFC1, CF3CFBr, CH3CH2, CHFCH2, 15 interest relate to the preparation of the two inhalant CHF2CF2, CFCICF2, CF2ClCFC), CF2ClCFBr, anesthetics mentioned above, as follows. CF2BrCF2, CF2BrCFC), CF2BrCFBr, CHFBrCF2, CHCl2CF2, CHClBrCF2 or Preparation of Enflurane Anesthetic, CHBr2CF2. CHFOCFCHFC1 20 The halogenated ether CF2HOCF2CFCl2 is a partic THE PRIOR ART ularly undesirable by-product of the presently No prior art is known that discloses or suggest the employed process for the preparation of enfluraneanes present process. thetic. It is readily reduced to enflurane in good yield by In Fluorine Chemistry Reviews, by Metille and Burton, the process of the present invention, as follows: p. 354, the authors describe the dehalogenation of CF3I. 25 to CF3H, using KOH in a solvent of high dielectric constant, specifically referring to ethanol. The use of CHFOCFCFCl2 + CH3OH + NaOH - Ge the reaction to dehalogenate CF3CF2I to CF3CF2H is also discussed. () The source article referred to by Metille and Burton 30 CHFOCF2CHFC -- NaCl + CH2O is Banus et al., J. Chem. Soc. 1951, pp. 60-64. This (enflurane anesthetic) publication states that it is known that the C-I bond in CF3I can undergo homolytic fission but that, apart from Using this reaction, a product stream from the pre decomposition, CF3Cl, CF2Cl2 and CHF2Cl "do not sently-employed process for producing enflurane, that show reactions involving the homolytic or heterolytic 35 contains this by-product I, can be upgraded by reacting fission of the carbon-chlorine bond." The publication in the product stream itself to convert the by-product to general stresses that the iodo compounds are unique as enflurane, in situ. The enflurane itself, that is present in compared to the corresponding bromo or chloro com the product stream, is not affected by the reaction. pounds. It would not, therefore, suggest the use of the In addition, the other halogenated ether by-products same type of reaction even for brominated, chlorinated, mentioned above, that are produced as "bottoms," can or fluorinated alkanes, let alone ethers. be further processed by distillation and chlorination to Young, U.S. Pat. No. 3,391,204, in his Example 11, obtain a mixture containing a high proportion of the describes the reaction: ether CHCl2OCF2CFCl2. Fluorination of this ether leads to I above, which can then be reacted in accor CuCl 45 dance with the invention to produce more enflurane, CF2CICF2Cl + TEA se CFCCF2H thus materially improving overall process yield and economics. where TEA represents triethanolamine. It should be noted that when the alkanol employed is Examples 12 and 13 describe generally similar methanol, 1.5 moles are required per mole of ether, so dehalogenations. Young says that alcohol may be pres 50 that the equations above and below, that employ metha ent, but characterizes the alcohol as an "inert' solvent, nol, are not balanced. The reason is that methanol un and his reaction did not operate on ethers, but rather on dergoes the Cannizzaro reaction. When other suitable halogenated alkanes. alkanols are employed which do not give a Cannizzaro In German Pat. No. 2,554,884, partial dechlorination reaction, the reaction requires one mole of the alkanol of F2CHOCFCICF2Cl, an ether, was accomplished by 55 the use of hydrogen and a catalyst of either palladium or to one mole of reactant ether.
Load more

Recommended publications
  • Callistephin Enhances the Protective Effects of Isoflurane on Microglial Injury Through Downregulation of Inflammation and Apoptosis
    802 MOLECULAR MEDICINE REPORTS 20: 802-812, 2019 Callistephin enhances the protective effects of isoflurane on microglial injury through downregulation of inflammation and apoptosis LILI ZHAO, SHIBIAO CHEN, TIANYIN LIU, XIUHONG WANG, HAIJIN HUANG and WEICHENG LIU Department of Anesthesiology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Received June 18, 2018; Accepted March 15, 2019 DOI: 10.3892/mmr.2019.10282 Abstract. Microglia are the major immune cells in the central enhanced the effects of isoflurane. Callistephin may therefore nervous system. Microglial activation can be beneficial or constitute a candidate drug agent that may target inflammatory detrimental depending on the stimuli and the physiopathological and growth regulatory signaling pathways, thus ameliorating environment. Microglial activation is involved in a variety certain aspects of neurodegenerative diseases. of neurodegenerative disorders. Different anesthetic agents have exhibited diverse effects on microglial activation and Introduction the engulfment process. The anthocyanin callistephin has been demonstrated to have antioxidant and anti‑inflammatory Microglial cells are the major immune cell in the central properties, and these were assessed in the present study, with a nervous system (CNS), responding against types of endog- focus on its effect on microglial activation. Mouse microglial enous and exogenous stimuli, including infection by bacteria, cells C8-4B were treated with 100 ng/µl lipopolysaccharide viruses, prions and β-amyloid plaques (1). Microglia are (LPS) and 1 ng/µl interferon-γ. Cells were subsequently treated activated upon exposure to different stimuli and, depending with 2% isoflurane, 100 µM callistephin or both. LPS promoted on the environmental context, this may be beneficial or detri- apoptosis in C8-B4 cells, and this was reduced following mental to the functionality and physiology of the CNS (2).
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • An Overview on “Stages of Anesthesia and Some Novel General Anesthetics Drug”
    Rohit Jaysing Bhor. et al. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 5(4), 2017, 132-140. Review Article ISSN: 2349 – 7106 Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page: www.ajrcps.com AN OVERVIEW ON “STAGES OF ANESTHESIA AND SOME NOVEL GENERAL ANESTHETICS DRUG” Rohit Jaysing Bhor *1 , Bhadange Shubhangi 1, C. J. Bhangale 1 1* Department of Pharmaceutical Chemistry, PRES’s College of Pharmacy Chincholi, Tal-Sinner, Dist-Nasik, Maharashtra, India. ABSTRACT Anesthesia is a painless performance of medical producers. There are both major and minor risks of anesthesia. Anesthesia is a state of temporary induced loss of sensation or awareness. It gives analgesia i.e. relief from pain or prevention of pain and paralysis. General anaesthesia is a medically induced state of unconsciousness. It gives loss of protective reflux. It is carried out to allow medical procedures or medical surgery. It can be classified into 3 types like Intravenous Anesthetics Drug; Miscellaneous Drug; and Inhalational anesthetic Drug. Sodium thiopental is an ultra-short-acting barbiturate and has been used commonly in the induction phase of anesthesia. Methohexital is an example of barbiturates derivatives. It is classified as short-acting, and has a rapid onset of action. KEYWORDS Anesthesia, Sodium thiopental, Methohexital and Propofol. Author for Correspondence: INTRODUCTON Anesthesia is a state of temporary induced loss of sensation or awareness. It gives analgesia i.e. relief 1 Rohit Jaysing Bhor, from pain or prevention of pain and paralysis . A patient under the effects of anesthetic drug is known Department of Pharmaceutical Chemistry, as anesthetized.
    [Show full text]
  • Visualizing Anesthesia-Induced Vasodilation of Cerebral Vasculature Using Multi-Exposure Speckle Imaging
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.26.174227; this version posted June 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Visualizing anesthesia-induced vasodilation of cerebral vasculature using multi-exposure speckle imaging Colin T. Sullendera, Lisa M. Richardsa, Fei Heb, Lan Luanb,c, Andrew K. Dunna,* aDepartment of Biomedical Engineering, University of Texas at Austin, 107 W. Dean Keeton Street Stop C0800, Austin, Texas, 78712, United States bDepartment of Electrical and Computer Engineering, Rice University, 6100 Main Street, Houston, TX, 77005, United States cDepartment of Bioengineering, Rice University, 6100 Main Street, Houston, TX, 77005, United States Abstract. Anesthetized animal models are used extensively during neurophysiological and behavioral studies despite systemic effects from anesthesia that undermine both accurate interpretation and translation to awake human physi- ology. In this paper, we characterize the impact of isoflurane on cerebral blood flow (CBF) during the induction of general anesthesia in awake mice using multi-exposure speckle imaging (MESI). We highlight the large anatomical changes caused by the vasodilatory inhalant with wide-field imagery and quantify the cortical hemodynamics with MESI across multiple subjects and imaging sessions. Compared to the awake state, we measured, on average, an 18% increase in surface vessel diameter accompanied by a 135% increase in vascular flux and 92% increase in parenchyma perfusion. These large alterations to the cortical vasculature and CBF are unrepresentative of normal physiology and provide further evidence that neuroscience experiments would benefit from transitioning to un-anesthetized awake animal models.
    [Show full text]
  • Pharmacological Classification of the Abuse-Related Discriminative
    Ashdin Publishing Journal of Drug and Alcohol Research ASHDIN Vol. 3 (2014), Article ID 235839, 10 pages publishing doi:10.4303/jdar/235839 Research Article Pharmacological Classification of the Abuse-Related Discriminative Stimulus Effects of Trichloroethylene Vapor Keith L. Shelton and Katherine L. Nicholson Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, P.O. Box 980613, Richmond, VA 23298, USA Address correspondence to Keith L. Shelton, [email protected] Received 10 December 2013; Revised 2 January 2014; Accepted 27 January 2014 Copyright © 2014 Keith L. Shelton and Katherine L. Nicholson. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Inhalants are distinguished as a class primarily based upon common means of administration suggests a homogeneity of a shared route of administration. Grouping inhalants according to mechanism and behavioral effects that may be scientifically their abuse-related in vivo pharmacological effects using the drug unwarranted. As an illustration of the inadequacy of this discrimination procedure has the potential to provide a more relevant classification scheme to the research and treatment community. simplistic taxonomic approach, consider the fact that if a Mice were trained to differentiate the introceptive effects of the similar system was applied to other common drugs of abuse, trichloroethylene vapor from air using an operant procedure. then tobacco, crack cocaine, and marijuana would be treated Trichloroethylene is a chlorinated hydrocarbon solvent once used as a single category. Instead, other classes of abused drugs as an anesthetic as well as in glues and other consumer products.
    [Show full text]
  • The Cardiovascular and Respiratory Effects of Isoflurane-Nitrous Oxide Anaesthesia
    THE CARDIOVASCULAR AND RESPIRATORY EFFECTS OF ISOFLURANE-NITROUS OXIDE ANAESTHESIA WILLIAM M. DOLAN, M.D.S, WENDELL C. STEVENS, M.D.,O EDMOND I. EGER, II, M.D.,* TnOlX~AS H. CROMWELL, M.D,, c* MICHAEL J. HALSEY, PH.D.,C* THOMAS F. SHAKESPEAlqE, Ik~.D.,c* AND RONALD D. MILLER, M.D. c* INTRODUCTION ISOFLURAnE (Forane| 1 chloro-2-2-2 trifluoroethyl, difluoromethyl ether), is a halogenated ether currently being evaluated for use as an inhalational anaesthetic. Its favourable properties include non-flammability, 1 relatively low blood and fat solubilities (blood-gas and oil-gas partitions of 1.4 and 99, respectively), 1,2 mole- cular stability resulting in resistance to dehydrohalogenation and hepatic meta- bolism, 1,~ lack of sensitization of the heart to catecholamines, 4 and favourable depression of neuromuscular function and potentiation of muscle relaxants. ~ However, isoflurane can produce profound depression of ventilation and blood pressure. ~ Since the concurrent use of nitrous oxide with halothane attenuates the hypotension and ventilatory depression caused by halothane, s,'~,l~ we asked whether nitrous oxide would produce similar changes towards awake values dur- ing isoflurane anaesthesia. METHODS We studied the cardiovascular and respiratory effects of anaesthesia with iso- flurane and 70 per cent nitrous oxide in eight healthy, unpremedicated volun- teers. The volunteers were 25 --4- 1 (SD) years of age and were informed of the purposes, procedures, and hazards of the study. The protocol was approved by the Committee on Human Experimentation of the University of California, San Francisco. A normal medical history, physical examination, chest roentgenogram, complete blood count, serum glutamic oxaloacetic transanainase and lactic de- hydrogenase were required before a volunteer was accepted for anaesthesia.
    [Show full text]
  • Synthetic Method for Fluoromethylation Of
    Europäisches Patentamt *EP001286941B1* (19) European Patent Office Office européen des brevets (11) EP 1 286 941 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07C 43/12, C07C 41/16, of the grant of the patent: C07C 41/22, C07C 41/28, 20.07.2005 Bulletin 2005/29 C07C 41/52, C07C 43/313 (21) Application number: 01939633.2 (86) International application number: PCT/US2001/017348 (22) Date of filing: 30.05.2001 (87) International publication number: WO 2001/092193 (06.12.2001 Gazette 2001/49) (54) SYNTHETIC METHOD FOR FLUOROMETHYLATION OF HALOGENATED ALCOHOLS VERFAHREN ZUR FLUORMETHYLIERUNG VON HALOGENIERTEN ALKOHOLEN PROCEDE DE SYNTHESE DE FLUOROMETHYLATION D’ALCOOLS HALOGENES (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU • BIENIARZ, Christopher MC NL PT SE TR Highland Park, IL 60035 (US) Designated Extension States: • RAMAKRISHNA, Kornepati, V. RO SI Libertyville, IL 60048 (US) (30) Priority: 01.06.2000 US 587421 (74) Representative: Modiano, Guido, Dr.-Ing. et al Modiano, Josif, Pisanty & Staub, (43) Date of publication of application: Baaderstrasse 3 05.03.2003 Bulletin 2003/10 80469 München (DE) (73) Proprietor: Abbott Laboratories (56) References cited: Abbott Park, IL 60064-6050 (US) EP-A- 0 822 172 GB-A- 1 250 928 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement.
    [Show full text]
  • Delivery of Carbon Monoxide Via Halogenated Ether Anesthetics
    Nitric Oxide 89 (2019) 93–95 Contents lists available at ScienceDirect Nitric Oxide journal homepage: www.elsevier.com/locate/yniox T Delivery of carbon monoxide via halogenated ether anesthetics ARTICLE INFO Keywords: Anesthetics CORM Carbon monoxide Heme oxygenase Desflurane Sevoflurane Organ transplantation Letter to the Editor across preclinical models. Whereas preclinical models have experi- mental flexibility, stringent safety constraints have prevented physi- The therapeutic potential of carbon monoxide (CO) has been well- cians from attaining high COHb levels in humans. Interestingly, a characterized over the past decades [1]. Organ transplantation is an widely used general anesthetic, desflurane, has been associated with exemplary unmet medical need where CO has emerged as a protective significantly increased intraoperative COHb levels ranging between 7% agent [2]. Translational efforts have focused on CO inhalation proto- and 36% when administered through dried carbon dioxide absorbents cols, carboxyhemoglobin infusion, heme oxygenase (HO) induction, [18]. Though 36% COHb is an extraordinary case, it seems possible that and local delivery of CO-releasing molecules (CORMs); however, a anesthesia protocols utilizing HEAs can be optimized to deliver a CO clinical breakthrough has yet to emerge [3]. Interestingly, halogenated payload to achieve high COHb levels in a clinical setting. ether anesthetics (HEAs) (Fig. 1) have been linked to elevated in- The phenomenon of CO being liberated from HEAs within an an- traoperative carboxyhemoglobin (COHb) levels [4,5]. A recent rando- esthesia machine apparatus has been well-documented [4]. The pro- mized clinical trial indicated patients receiving HEAs have demon- posed mechanism for desflurane is specifically dependent upon are- strated improved graft survival prognosis relative to patients receiving action with partially dried carbon dioxide absorbents (< 4.8% water a different anesthetic.
    [Show full text]
  • Toxicological Profile for 1,1-Dichloroethene
    1,1-DICHLOROETHENE 125 CHAPTER 8. REFERENCES *ACGIH. 2001. Documentation of the TLVs and BEIs for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists. May 3, 2017. *ACGIH. 2016. TLVs and BEIs based on the documentation of the threshold limit values for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists. May 3, 2017. Adeniji SA, Kerr JA, Williams MR. 1981. Rate constants for ozone-alkene reactions under atmospheric conditions. Int J Chem Kinet 13:209-217. *Aelion CM, Conte BC. 2004. Susceptibility of residential wells to VOC and nitrate contamination. Environ Sci Technol 38(6):1648-1653. *Andersen ME, Jenkins J. 1977. Oral toxicity of 1,1-dichloroethylene in the rat: Effects of sex, age, and fasting. Environ Health Perspect 21:157-163. *Andersen ME, Jones RA, Jenkins LJ. 1978. The acute toxicity of single, oral doses of 1,1-dichloro- ethylene in the fasted male rat: Effect of induction and inhibition of microsomal enzyme activities on mortality. Toxicol Appl Pharmacol 46:227-234. Andersen ME, Thomas OE, Gargas ML, et al. 1980. The significance of multiple detoxification pathways for reactive metabolites in the toxicity of 1,1-dichloroethylene. Toxicol Appl Pharmacol 52:422-432. +*Anderson D, Hodge MCE, Purchase IFH. 1977. Dominant lethal studies with the halogenated olefins vinyl chloride and vinylidene dichloride in male CD-1 mice. Environ Health Perspect 21:71-78. Apfeldorf R, Infante PF. 1981. Review of epidemiologic study results of vinyl chloride-related compounds. Environ Health Perspect 41:221-226.
    [Show full text]
  • Evaluation of the Antinociceptive Properties of Hyptis Crenata Pohl (Brazilian Mint)
    Evaluation of the Antinociceptive Properties of Hyptis crenata Pohl (Brazilian Mint) Thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy By Graciela Silva Rocha Institute of Neuroscience (ION) July 2013 Abstract This project aimed to investigate the main traditional use of the plant Hyptis crenata (HC) and evaluate its activity in a pre-clinical trial. A traditional use survey was carried out in two municipalities in Brazil, interviewing 20 people. The results showed that the main use of HC is for pain relief (19/20). The main method used for its preparation was decoction extract (11/20). The antinociceptive activity of HC decoction extract was evaluated showing that HC 15 mg/kg (p.o.) and HC 150 mg/kg (p.o.) increased delay in withdrawal response in the Hargreaves thermal withdrawal test by 29% and 28% respectively and decreased writhing occurrences induced by acetic acid by 70% and 71% (p<0.05), when compared to vehicle. These treatments were examined in the acetic acid writhing test for their effects on c-fos protein expression. The results showed that HC 150 mg/kg (p.o.) decreased c-fos expression in the hypothalamic paraventricular nucleus by 40% (p<0.05). This study also evaluated the HC doses 1 mg/kg (p.o.), 5 mg/kg (p.o.) and 45 mg/kg (p.o.) to assess the dose-response effect. HC dose- dependently induced antinociception in both animal models from 0 mg/kg (p.o.) to 15 mg/kg (p.o.), until a plateau response occurred between 15 mg/kg and 45 mg/kg (thermal withdrawal test p=0.0002 and writhing inhibition p=0.4725).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,245,949 B1 Bieniarz Et Al
    USOO6245949B1 (12) United States Patent (10) Patent No.: US 6,245,949 B1 Bieniarz et al. (45) Date of Patent: Jun. 12, 2001 (54) SYNTHETIC METHOD FOR THE 4,874,901 10/1989 Halpern et al. ...................... 568/683 FLUOROMETHYLATION OF ALCOHOLS 4,996,371 2/1991 Halpern et al. ...................... 568/683 5,705,710 1/1998 Baker et al. ......................... 568/683 (75) Inventors: Christopher Bieniarz, Highland Park; 5,789,630 8/1998 Baker et al. ......................... 570/141 Kornepati V. Ramakrishna, 5,811,596 9/1998 Kawai et al. ........................ 568/683 Libertyville, both of IL (US) 5,886,239 3/1999 Kudzma et al. ..................... 568/684 5,969,193 * 10/1999 Terrell .................................. 568/683 5.990,359 * 11/1999 Ryan et al. .......................... 568/683 (73) Assignee: Abbott Laboratories, Abbott Park, IL 6,100,434 8/2000 Bieniarz et al. ..................... 568/683 (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 0 042 412 * 12/1981 (EP). U.S.C. 154(b) by 0 days. * cited by examiner Primary Examiner Johann Richter (21) Appl. No.: 09/587,414 (74) Attorney, Agent, or Firm-Brian R. Woodworth (22) Filed: Jun. 1, 2000 (57) ABSTRACT (51) Int. Cl." ............................ C07C 41/01; CO7C 41/09 A method for fluoromethylating halogenated alcohols. The (52) U.S. Cl. .................. 568/683; 568/684; 568/685 method includes the Step of providing an alpha-halogenated (58) Field of Search ..................................... 568/683, 684, alcohol of the formula RC(CX), OH, wherein R' is 568/685 Selected from the group consisting of hydrogen and alkyl groups.
    [Show full text]
  • HCN Subunit-Specific and Camp-Modulated Effects of Anesthetics on Neuronal Pacemaker Currents
    The Journal of Neuroscience, June 15, 2005 • 25(24):5803–5814 • 5803 Cellular/Molecular HCN Subunit-Specific and cAMP-Modulated Effects of Anesthetics on Neuronal Pacemaker Currents Xiangdong Chen,1 Jay E. Sirois,2 Qiubo Lei,1 Edmund M. Talley,1 Carl Lynch III,2 and Douglas A. Bayliss1,2 Departments of 1Pharmacology and 2Anesthesiology, University of Virginia, Charlottesville, Virginia 22908 General anesthetics have been a mainstay of surgical practice for more than 150 years, but the mechanisms by which they mediate their important clinical actions remain unclear. Ion channels represent important anesthetic targets, and, although GABAA receptors have emerged as major contributors to sedative, immobilizing, and hypnotic effects of intravenous anesthetics, a role for those receptors is less certain in the case of inhalational anesthetics. The neuronal hyperpolarization-activated pacemaker current (Ih ) is essential for oscilla- tory and integrative properties in numerous cell types. Here, we show that clinically relevant concentrations of inhalational anesthetics modulate neuronal Ih and the corresponding HCN channels in a subunit-specific and cAMP-dependent manner. Anesthetic inhibition of Ih involves a hyperpolarizing shift in voltage dependence of activation and a decrease in maximal current amplitude; these effects can be ascribed to HCN1 and HCN2 subunits, respectively, and both actions are recapitulated in heteromeric HCN1–HCN2 channels. Mutagen- esis and simulations suggest that apparently distinct actions of anesthetics on V1/2 and amplitude represent different manifestations of a single underlying mechanism (i.e., stabilization of channel closed state), with the predominant action determined by basal inhibition imposed by individual subunit C-terminal domains and relieved by cAMP.
    [Show full text]